Author

S. Caratelli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Ottaviani· 3 shared C. Cenciarelli· 3 shared G. Lanzilli· 3 shared G. Sconocchia· 3 shared R. Arriga· 3 shared T. Sconocchia· 3 shared A. Venditti· 2 shared D. Lauro· 2 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Ottaviani

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologybioRxivPreprintDec 22, 2021

ANTIBODY-INDEPENDENT ANTITUMOR EFFECTS OF CD32A-CHIMERIC RECEPTOR T CELLS: IMPLICATIONS FOR BREAST CANCER PROGNOSIS AND TREATMENT.

G. Sconocchia, G. Lanzilli, V. Cesarini…·G. C. Spagnoli

This study shows CD32A-chimeric receptor T cells can identify CD32A ligands, predict breast cancer sensitivity, and improve prognosis without antibodies.

DOI 10.1101/2021.12.22.473841

humanbulk RNA-seq

𝕏 PostBluesky

ImmunologybioRxivMar 26, 2019

CD16-158-VALINE CHIMERIC RECEPTOR T CELLS OVERCOME THE RESISTANCE OF KRAS-MUTATED COLORECTAL CARCINOMA CELLS TO CETUXIMAB

R. Arriga, S. Caratelli, G. Lanzilli…·G. Sconocchia

This study evaluates CD16-158-VALINE chimeric receptor T cells for overcoming cetuximab resistance in KRAS-mutated colorectal cancer, finding they enhance IFNγ and TNF release and control tumor growth in mice.

DOI 10.1002/ijc.32618

mouseproteomics

𝕏 PostBluesky

ImmunologybioRxivPreprintMar 18, 2019

ELIMINATION OF EGFR-OVEREXPRESSING CANCER CELLS BY CD32 CHIMERIC RECEPTOR T CELLS IN COMBINATION WITH CETUXIMAB OR PANITUMUMAB

S. Caratelli, R. Arriga, T. Sconocchia…·G. Sconocchia

This study shows CD32131R-CR T cells can eliminate EGFR-overexpressing cancer cells when combined with cetuximab or panitumumab, outperforming CD16158F-CR T cells.

DOI 10.1101/581017

humanproteomics

𝕏 PostBluesky